Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wouter Haazen

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
AIDS (London, England)|June 6, 2014
A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy womenAnnalene Nel, Wouter Haazen, Jeremy Nuttall, et al.
Vaccine|September 9, 2017
Erratum to "Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adults" [Vaccine 34 (2016) 3156-3163]Geert Leroux-Roels, Pierre Van Damme, Wouter Haazen, et al.
Vaccine|May 3, 2016
Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adultsGeert Leroux-Roels, Pierre Van Damme, Wouter Haazen, et al.
The Journal of Infectious Diseases|August 28, 2020
Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older AdultsJerald Sadoff, Els De Paepe, Wouter Haazen, et al.
British Journal of Clinical Pharmacology|February 24, 2017
Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studiesStephen Norris, Steven Ramael, Ippei Ikushima, et al.
Open Forum Infectious Diseases|August 23, 2023
Safety, Reactogenicity, Immunogenicity, and Dose Selection of 10-Valent Extraintestinal Pathogenic <i>Escherichia coli</i> Bioconjugate Vaccine (VAC52416) in Adults Aged 60-85 Years in a Randomized, Multicenter, Interventional, First-in-Human, Phase 1/2a StudyCarlos A Fierro, Michal Sarnecki, Joachim Doua, et al.
British Journal of Haematology|February 19, 2008
A human anti-D monoclonal antibody selected for enhanced FcgammaRIII engagement clears RhD+ autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodiesRoland Beliard, Tony Waegemans, Dominique Notelet, et al.
Journal of the American College of Cardiology|May 7, 2016
Restarting Dabigatran Etexilate 24 h After Reversal With Idarucizumab and Redosing Idarucizumab in Healthy VolunteersStephan Glund, Joachim Stangier, Joanne van Ryn, et al.
Journal of Clinical Pharmacology|January 25, 2007
Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjectsGoutam C Mistry, Arthur J Bergman, Wen-Lin Luo, et al.
NPJ Vaccines|June 14, 2024
A randomized phase 1/2a trial of ExPEC10V vaccine in adults with a history of UTICarlos A Fierro, Michal Sarnecki, Bart Spiessens, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
AIDS (London, England)|June 6, 2014
A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy womenAnnalene Nel, Wouter Haazen, Jeremy Nuttall, et al.
Vaccine|September 9, 2017
Erratum to "Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adults" [Vaccine 34 (2016) 3156-3163]Geert Leroux-Roels, Pierre Van Damme, Wouter Haazen, et al.
Vaccine|May 3, 2016
Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adultsGeert Leroux-Roels, Pierre Van Damme, Wouter Haazen, et al.
The Journal of Infectious Diseases|August 28, 2020
Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older AdultsJerald Sadoff, Els De Paepe, Wouter Haazen, et al.
British Journal of Clinical Pharmacology|February 24, 2017
Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studiesStephen Norris, Steven Ramael, Ippei Ikushima, et al.
Open Forum Infectious Diseases|August 23, 2023
Safety, Reactogenicity, Immunogenicity, and Dose Selection of 10-Valent Extraintestinal Pathogenic <i>Escherichia coli</i> Bioconjugate Vaccine (VAC52416) in Adults Aged 60-85 Years in a Randomized, Multicenter, Interventional, First-in-Human, Phase 1/2a StudyCarlos A Fierro, Michal Sarnecki, Joachim Doua, et al.
British Journal of Haematology|February 19, 2008
A human anti-D monoclonal antibody selected for enhanced FcgammaRIII engagement clears RhD+ autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodiesRoland Beliard, Tony Waegemans, Dominique Notelet, et al.
Journal of the American College of Cardiology|May 7, 2016
Restarting Dabigatran Etexilate 24 h After Reversal With Idarucizumab and Redosing Idarucizumab in Healthy VolunteersStephan Glund, Joachim Stangier, Joanne van Ryn, et al.
Journal of Clinical Pharmacology|January 25, 2007
Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjectsGoutam C Mistry, Arthur J Bergman, Wen-Lin Luo, et al.
NPJ Vaccines|June 14, 2024
A randomized phase 1/2a trial of ExPEC10V vaccine in adults with a history of UTICarlos A Fierro, Michal Sarnecki, Bart Spiessens, et al.
Pageof 2